This past year, Ron took over the role of Chair of BIO, the Biotechnology Innovation Organization. From that vantage point, he comments on the high drama in 2015 that has entertained – and sometimes threatened – the industry. He discusses inter partes review, the right and wrong conversations on drug pricing, and the choices that determine the pace of R&D within our ecosystem of brilliant science and entrepreneurship. He also projects some hot trends and throws down the gauntlet for biotech in NY. If you listen carefully, you can hear him pounding the table.
This episode, Part 2 of the two-part interview, picks up where Part 1 left off, on the subject of social media’s role in biotech.